MannKind Corporation (NASDAQ:MNKD)’s shares fell 3.35% to $5.20. The company on Feb. 18 reported financial results for the fourth quarter and full year ended December 31, 2013. The net loss applicable to common stockholders for fiscal year 2013 was $(191.5) million, or $(0.64) per share based on 299.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $(169.4) million, or $(0.94) per share based on 180.9 million weighted average shares outstanding for fiscal year 2012. MannKind Corporation (NASDAQ:MNKD) shares after opening at $5.64 moved to $5.75 on last trade day and at the end of the day closed at $4.83. Company price to cash ratio as 23.04. MannKind Corporation (NASDAQ:MNKD) showed a negative weekly performance of -17.72%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares dropped 7.14% to $3.38. The company on Mar. 26 announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares moved down 9.89% in last trading session and was closed at $3.28, while trading in range of $ 3.15 – 3.64. Inovio Pharmaceuticals Inc (NYSEMKT:INO) year to date (YTD) performance is 13.10%.
EXACT Sciences Corporation (NASDAQ:EXAS)’s shares climbed 3.42% to $14.22. The company on Mar. 27 announced that the U.S. Food and Drug Administration’s (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard, the company’s stool-based DNA (sDNA), non-invasive colorectal cancer screening test. In the company’s 10,000-patient, 90-site DeeP-C pivotal trial—one of the most extensive colorectal cancer screening studies ever conducted in the United States—Exact Sciences’ Cologuard found 92.3% of colorectal cancer in average risk patients based on a combination of DNA and hemoglobin markers. EXACT Sciences Corporation (NASDAQ:EXAS) weekly performance is -11.19%. On last trading day company shares ended up $12.86. EXACT Sciences Corporation (NASDAQ:EXAS) distance from 50-day simple moving average (SMA50) is -5.10%. Analysts mean target price for the company is $17.33.
Leave a Reply